Trial
NCT04498468
Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Johns Hopkins University
Collaborators
—
Condition
Dry Eye
Intervention
Sustained Release Dexamethasone, 0.4 mg
Why stopped
The study was terminated prematurely due to administrative reasons; loss of several research personnel. Because of strict eligibility criteria, the investigators anticipated delays in completing enrollment and therefore decided to terminate early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-15